Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection? episode artwork

EPISODE · Jun 18, 2015 · 10 MIN

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?

from GRACEcast · host cancerGRACE Meetings

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?

Episode metadata supplied by the publisher feed · Published Jun 18, 2015

Embed this episode

NOW PLAYING

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?

0:00 10:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 10 minutes long.

When was this GRACEcast episode published?

This episode was published on June 18, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!